Lineage Cell Therapeutics Announces Extension of OpRegen® Development Grant From Israel Innovation Authority

CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that as a result of continued clinical progress, the Israel Innovation Authority (IIA) has extended its previously awarded development grant in support of OpRegen®, the Company’s retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of dry age-related